Table 2.
Clinical trials evaluating combination of anti-angiogenic and immunotherapies
| Clinical Trial Identifier | Phase | Status | Angiogenic Therapy | Immunotherapy | Other Drugs | Cancer |
|---|---|---|---|---|---|---|
| NCT05488522 | I | Recruiting | Bevacizumab | Atezolizumab | Stereotactic body radiotherapy (SBRT) | Advanced hepatocellular carcinoma (HCC) |
| NCT02873195 | II | Active | Bevacizumab | Atezolizumab | Capecitabine | Refractory metastatic colorectal cancer |
| NCT04356729 | II | Recruiting | Bevacizumab | Atezolizumab | – | Unresectable or metastatic stage II or IV cutaneous melanoma |
| NCT03762018 | III | Active | Bevacizumab | Atezolizumab | Standard chemotherapy | Malignant pleural mesothelioma |
| NCT03074513 | II | Active | Bevacizumab | Atezolizumab | – | Rare solid tumors |
| NCT02210117 | I | Active | Bevacizumab | Nivolumab, Ipilimumab | – | Resectable metastatic kidney cancer |
| NCT06083844 | II | Recruiting | Bevacizumab | Pembrolizumab | Low-dose cyclophosphamide | High grade ovarian cancer with minimal residual disease after frontline treatment |
| NCT03175432 | II | Active | Bevacizumab | Atezolizumab | Cobimetinib | Untreated melanoma with brain metastasis |
| NCT04721132 | II | Recruiting | Bevacizumab | Atezolizumab | – | Resectable liver cancer |
| NCT02921269 | II | Completed | Bevacizumab | Atezolizumab | – | Recurrent, persistent, or metastatic cervical cancer |
| NCT03141684 | II | Recruiting | Bevacizumab | Atezolizumab | Advanced unresectable alveolar soft part sarcoma | |
| NCT01950390 | II | Active | Bevacizumab | Ipilimumab | – | Stage III-IV melanoma |
| NCT04981509 | II | Recruiting | Bevacizumab, Erlotinib | Atezolizumab | – | Advanced stage kidney cancer |
| NCT05211323 | II | Recruiting | Bevacizumab | Atezolizumab | Gemcitabine, cisplatin | Advanced unresectable liver cancer |
| NCT02997228 | III | Recruiting | Bevacizumab | Atezolizumab | Combination chemotherapy | Mismatch repair deficient, metastatic, colorectal cancer |
| NCT02853318 | II | Completed | Bevacizumab | Pembrolizumab | Low-dose cyclophosphamide | Recurrent ovarian, fallopian tube, or primary peritoneal cancer |
| NCT05468359 | I/II | Recruiting | Bevacizumab | Atezolizumab | Cyclophosphamide, sorafenib | Pediatric solid tumors |
| NCT03396926 | II | Active | Bevacizumab | Pembrolizumab | Capecitabine | Locally advanced, metastatic, or nonresectable microsatellite stable colorectal cancer |
| NCT03172754 | I/II | Recruiting | Axitinib | Nivolumab | – | Advanced renal cell carcinoma |
| NCT04996823 | II | Recruiting | Axitinib | Ipilimumab | – | Advanced melanoma |
| NCT04338269 | III | Active | Cabozantinib | Atezolizumab | – | Inoperable, locally advanced, or metastatic renal cell carcinoma |
| NCT05805501 | II | Recruiting | Axitinib | Triagolumab, Tobemstomig, Pembrolizumab | – | Previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma |
| NCT04493203 | II | Recruiting | Axitinib | Nivolumab | – | Unresectable stage III or IV melanoma |
| NCT02133742 | Ib | Completed | Axitinib | Pembrolizumab | – | Advanced renal cell cancer |
| NCT04919629 | II | Recruiting | Bevacizumab | Pembrolizumab | APL-2 | Recurrent ovarian, fallopian tube or primary peritoneal cancer |
| NCT05231122 | II | Recruiting | Bevacizumab | Pembrolizumab, anti-CD40 CDX-1140 | – | Recurrent ovarian cancer |
| NCT02636725 | II | Completed | Axitinib | Pembrolizumab | – | Advanced alveolar soft part sarcoma and soft tissue sarcomas |
| NCT04370509 | II | Recruiting | Axitinib | Pembrolizumab | – | Locally advanced metastatic clear cell kidney cancer |
| NCT03092856 | II | Active | Axitinib | Anti-OX40 | – | Metastatic kidney cancer |